# Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)

> **NCT00623558** · PHASE2 · COMPLETED · sponsor: **Seoul National University Hospital** · enrollment: 92 (actual)

## Conditions studied

- Head and Neck Neoplasm

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Docetaxel
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT00623558
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2012-11
- **Final completion:** 2013-08
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2013-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00623558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00623558, "Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00623558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*